Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer

Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

(2017) R. A. Burger et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Utility of CA-125 for Maintenance Therapy in the Treatment of Advanced Stage Ovarian Carcinoma

(2010) John P. Micha et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A review of the current evidence for maintenance therapy in ovarian cancer

(2009) Talia Foster et al.   GYNECOLOGIC ONCOLOGY

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial

(2009) Maurie Markman et al.   GYNECOLOGIC ONCOLOGY

Maintenance Therapy for Ovarian Cancer: Of Helsinki and Hippocrates

(2009) William Patrick McGuire   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

(2009) Michael A. Bookman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1

(2009) Sergio Pecorelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved survival time: What can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?

(2008) Lan Huang et al.   CANCER

Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors

(2008) S. Zhang et al.   CANCER RESEARCH

Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer

(2008) Jonathan Berek et al.   JOURNAL OF CLINICAL ONCOLOGY

CA125 Velocity at Relapse is a Highly Significant Predictor of Survival Post Relapse: Results of a 5-year Follow-up Survey to a Randomized Placebo-controlled Study of Maintenance Oregovomab Immunotherapy in Advanced Ovarian Cancer

(2008) Jonathan S. Berek et al.   JOURNAL OF IMMUNOTHERAPY